Biologic Therapies in Severe Asthma: Current Landscape, Clinical Evidence, and Future Directions
Authors:
- Yanki K. OkuducuYOYanki K. Okuducu
- T. Bernard KinaneTKT. Bernard Kinane
Open Access
- 28 December 2025
- journal article
- Published by Springer Nature in Current Pediatrics Reports
- Vol. 13 (1)
Abstract
Plain Language Background: Biologic therapies have transformed the management of severe asthma, particularly for patients with Type 2 (T2) inflammation. These targeted monoclonal antibodies offer a personalized approach for patients with eosinophilic or allergic phenotypes who remain uncontrolled despite high-dose inhaled corticosteroids and additional controller medications. Recent updates in guidelines, such as GINA 2025, reflect the growing integration of these therapies into asthma treatment algorithms. Objective: To provide a comprehensive review of current biologic options for severe asthma, including patient selection strategies, clinical efficacy, safety profiles, and areas of ongoing investigation. Methods: We performed a narrative synthesis of pivotal trials, real-world evidence, and recent guideline updates on five FDA-approved biologics—omalizumab, mepolizumab, benralizumab, dupilumab, and tezepelumab—alongside emerging data on depemokimab. Clinical eligibility criteria, mechanism of action, biomarker guidance, and outcome measures were compared. Emphasis was placed on individualized therapy and endotype-driven decision-making. Results: All biologics demonstrated significant reductions in exacerbation rates, oral corticosteroid (OCS) use, and improved asthma control in appropriate T2-high populations. Dupilumab and tezepelumab showed additional benefits on lung function and broader applicability across biomarker thresholds. Depemokimab, a long-acting anti-IL-5 agent, has shown promising efficacy in the SWIFT-1 and SWIFT-2 trials, supporting semi-annual dosing and sustained eosinophil suppression. Real-world studies reinforce clinical trial data, and safety profiles were favorable, with minor adverse events in a limited number of patients. Conclusion: Biologic therapies have redefined care for patients with severe T2 asthma, enabling biomarker-guided precision medicine. Despite significant progress, gaps remain in treating T2-low asthma, pediatric populations, and long-term treatment strategies. Ongoing research into omics-based predictors, dual-target therapies, and cost-accessibility will shape future asthma management paradigms.Keywords
This publication has 83 references indexed in Scilit:
- Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded IndicationsPharmacoepidemiology and Drug Safety, 2024
- The new biologic drugs: Which children with asthma should get what?Pediatric Pulmonology, 2024
- Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)American Journal of Clinical Dermatology, 2022
- Dupilumab: A Review in Chronic Rhinosinusitis with Nasal PolypsDrugs, 2020
- Roles of Periostin in Asthma2019
- Dupilumab (Dupixent) for AsthmaJAMA, 2019
- Understanding Asthma Phenotypes, Endotypes, and Mechanisms of DiseaseClinical Reviews in Allergy & Immunology, 2018
- Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe AsthmaAdvances in Therapy, 2018
- Omalizumab for asthma in adults and childrenCochrane Database of Systematic Reviews, 2014
- Anti-IgE for chronic asthma in adults and children2006